TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06513546: A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of ALS

Sponsor: PLL TX AUSTRALIA PTY LTD · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 153 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT06513546 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06513546 Rescue Dossier →